Market News & Trends
Yamo Pharmaceuticals Presents Results from Phase 2 Study
Yamo Pharmaceuticals, LLC recently announced the presentation of results from a Phase 2 study with L1-79 in the treatment of ASD. A poster, titled An…
Elligo Health Research Launches Novel IntElligo Research Stack Clinical Technology
Elligo Health Research recently announced the launch of its innovative IntElligo Research Stack clinical technology. This standards-based technology platform, which powers the System of Accelerated…
ProBioGen & Vaccitech Sign License Agreement
ProBioGen AG and Vaccitech, Ltd. jointly announced signing a license agreement in which Vaccitech will gain access to ProBioGen’s proprietary technology platform based on the…
Road Ahead Still Difficult for Biosimilar Producers in the US Despite New FDA Guidance on Interchangeability
Following news that the FDA has finalized its guidance on interchangeable biosimilars, Rose Joachim, PhD, Senior Immunology Pharma Analyst at GlobalData, a leading data and…
Codexis Announces CodeEvolver Technology Transfer & License Agreement With Global Pharmaceutical Leader
Codexis, Inc. recently announced the signing of a CodeEvolver platform agreement with Novartis. Under the terms of the agreement, Codexis has granted a non-exclusive license…
Adaptimmune & Alpine Immune Sciences Announce Collaboration & License Agreement
Adaptimmune Therapeutics plc and Alpine Immune Sciences, Inc. recently announced a collaboration and license agreement to develop next-generation SPEAR T-cell products that incorporate Alpine’s secreted…
Bone Sci Bio Presents Breakthrough Solutions for Bone Healing
Bone Sci Bio introduces PeptOss, a novel solution for bone treatment. The new product promotes formation and repair of bone tissue and enables controlled delivery of drugs, such as antibiotics or chemotherapy, directly to the bone, for various orthopedic and dental applications.
Cybrexa Therapeutics’ alphalex Platform Enables Tumor Targeting of Multiple PARP Inhibitors
Cybrexa Therapeutics recently announced preclinical data supporting the potential of its proprietary alphalex technology platform.
Caris Life Sciences Receives FDA Breakthrough Device Designation
Caris Life Sciences recently announced the US FDA has granted Breakthrough Device designation for the company’s MI Transcriptome companion diagnostic (CDx) test. Designed to detect…
Merus Announces First Patient Treated in Phase 1 Clinical Trial for Advanced Solid Tumors
Merus N.V. recently announced the first patient has been treated in its Phase 1 trial evaluating safety, tolerability, and preliminary efficacy of MCLA-145 for the…
Chinese Patent Office Issues Notice of Acceptance for Multiwavelength PhotoDynamic Therapy
Theralase Technologies Inc., a clinical stage pharmaceutical company dedicated to the research and development of light activated PhotoDynamic Compounds (PDCs) and their associated drug formulations…
Sarepta Announces Agreement With Nationwide Children’s Hospital for Rights to its Gene Therapy Program
Sarepta Therapeutics, Inc. recently announced it has recently signed an agreement with the Research Institute at Nationwide Children’s Hospital (Nationwide Children’s) giving Sarepta the exclusive…
Octapharma Study Demonstrates Cutaquig Efficacy & Safety
Octapharma presented clinical research results at the Clinical Immunology Society Annual Meeting in Atlanta demonstrating the efficacy and safety of cutaquig [Immune Globulin Subcutaneous (Human)…
Merck Announces Results from Phase 2 Trial
Merck recently announced results from a Phase 2 trial (NCT02982972) evaluating the safety, tolerability, and immunogenicity of V114, the company’s investigational 15-valent pneumococcal conjugate vaccine,…
HOOKIPA Achieves Research Milestone in Collaboration & License Agreement With Gilead
HOOKIPA Pharma Inc. recently announced it has achieved a further research milestone in its collaboration and license agreement with Gilead Sciences, Inc. for development of a therapeutic hepatitis B virus (HBV) vaccine.
RedHill Biopharma Submits NDA for for H. Pylori Infection Drug
RedHill Biopharma Ltd. recently announced that, following a positive pre-NDA meeting held recently with the US FDA, it has submitted a New Drug Application (NDA) to the FDA for Talicia (RHB-105) for the treatment of H. pylori infection.
Akcea & Ionis Announce European Union Drug Approval for Ultra-Rare Disease
Akcea Therapeutics, Inc. and Ionis Pharmaceuticals, Inc. recently announced that WAYLIVRA has received conditional marketing authorization from the EC as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk for pancreatitis, in whom response to diet and triglyceride-lowering therapy has been inadequate.
Eloxx Pharmaceuticals Presents Positive New Data at ARVO
Eloxx Pharmaceuticals, Inc. recently presented new findings related to preclinical inherited retinal disease therapeutic development at the ARVO 2019 Annual Meeting in Vancouver, BC, on…
Calixar Signs Exclusive Licensing Agreement With Regeneron
Calixar SAS (Calixar), a biotechnology company specialized in native membrane protein stabilization, recently announced it has entered into an exclusive licensing agreement with Regeneron Pharmaceuticals,…
Emendo Biotherapeutics Enters Licensing Option Agreement With Takeda
Emendo Biotherapeutics Inc. recently announced the company signed a licensing option agreement with Takeda Pharmaceutical Company Limited. As part of the transaction, Emendo will receive…
